Evidence map›Paper›PMID 39963344›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2025

Induced mesenchymal stem cells generated from periodontal ligament fibroblast for regenerative therapy.

Hemanathan Vembuli, Sheeja Rajasingh, Patrick Nabholz, Jefferson Guenther, Brian R Morrow, Margaret M Taylor, Marziyeh Aghazadeh, Vinoth Sigamani, Johnson Rajasingh

Abstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cyotoxicity of Etidronate as an Endodontic Chelator Against Periodontal Ligament Fibroblast.Australian endodontic journal : the journal of the Australian Society of Endodontology Inc · 2026
    Article
  2. Review
  3. Experimental Biology and medicine conference thematic issue introduction.Experimental biology and medicine (Maywood, N.J.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hemanathan VembuliDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Sheeja RajasinghDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Patrick NabholzDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Jefferson GuentherDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Brian R MorrowDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Margaret M TaylorDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Marziyeh AghazadehDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Vinoth SigamaniDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.
Johnson RajasinghDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, United States.

Funding

scaRNA Modified Induced Pluripotent Stem Cell-Derived Cardiomyocytes or Exosomes Therapy for Chronic Ischemic Cardiomyopathy PatientsR01HL141345 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, RAJASINGH · 2019 to 2022
$1.5M
NHLBI NIH HHS R01 HL141345
6 · The paper itself

Abstract

Bone fractures and bone loss represent significant global health challenges, with their incidence rising due to an aging population. Despite autologous bone grafts remain the gold standard for treatment, challenges such as limited bone availability, immune reactions, and the risk of infectious disease transmission have driven the search for alternative cell-based therapies for bone regeneration. Stem cells derived from oral tissues and umbilical cord mesenchymal stem cells (MSCs) have shown potential in both preclinical and clinical studies for bone tissue regeneration. However, their limited differentiation capacity and wound healing abilities necessitate the exploration of alternative cell sources. In this study, we generated induced pluripotent stem cells (iPSCs) using a safe, nonviral and mRNA-based approach from human periodontal ligament fibroblasts (PDLF), an easily accessible cell source. These iPSCs were subsequently differentiated into MSCs, referred to as induced MSCs (iMSCs). The resulting iMSCs were homogeneous, highly proliferative, and possessed anti-inflammatory properties, suggesting their potential as a superior alternative to traditional MSCs for regenerative therapy. These iMSCs demonstrated trilineage differentiation potential, giving rise to osteocytes, chondrocytes, and adipocytes. The iMSC-derived osteocytes (iOSTs) were homogeneous, patient-specific and showed excellent attachment and growth on commercial collagen-based membranes, highlighting their suitability for bone tissue regeneration applications. Given their promising characteristics compared to traditional MSCs, PDLF-derived iMSCs are strong candidates for future clinical studies in bone regeneration and other regenerative dental therapies.

Indexed as

FibroblastsInduced Pluripotent Stem CellsMesenchymal Stem CellsPeriodontal LigamentRegenerative MedicineCell DifferentiationCells, CulturedHumansOsteocytesdifferentiationinduced pluripotent stem cellsmesenchymal stem cellsosteocytesregenerative therapy

Identifiers

PMID39963344
PMCPMC11830513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.